Real-World Treatment of Extracranial Carotid Artery Disease With the ENROUTE™ Transcarotid Neuroprotection System
← catalyst calendarNCT07455747 · readout ≤ 651 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
5,000estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jul 2026 | estimated | When the study began enrolling |
| Primary completion | May 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Extracranial Carotid Artery Disease
- TCAR
- Transcarotid Artery Revascularization
Intervention
- Device: Use of ENROUTE™ Transcarotid Neuroprotection System in conjunction with any commercially available Boston Scientific stent marketed for treatment of carotid artery disease
Primary outcome
what the primary-completion date above is the date OFMajor Adverse Events
measured within 30 days (death, stroke, or MI); within 31-365 days (ipsilateral stroke)
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed